53207-60-6

Usage

Uses

1. Used in Pharmaceutical Industry:
1-(4-Cyclohexylphenyl)-2-methylpropan-1-one 97+% is used as a precursor for the preparation of thiosemicarbazone compounds, which are known as tyrosinase inhibitors. Tyrosinase is an enzyme involved in the production of melanin, and its inhibition can be beneficial in the treatment of hyperpigmentation and other skin conditions. 1-(4-CYCLOHEXYLPHENYL)-2-METHYLPROPAN-1-ONE 97+%'s role in the synthesis of these inhibitors makes it a valuable asset in the development of pharmaceuticals targeting skin-related disorders.
2. Used in Chemical Synthesis:
In addition to its pharmaceutical applications, 1-(4-Cyclohexylphenyl)-2-methylpropan-1-one 97+% can also be utilized in the synthesis of various organic compounds. Its unique structure allows for further chemical reactions and modifications, making it a versatile building block in the creation of new molecules with potential applications in various fields, such as materials science, agrochemicals, and specialty chemicals.

Upstream product

• 827-52-1 1-phenyl-1-cyclohexane 
• 79-30-1 isobutyryl chloride 

Downstream Products

• 95711-80-1 3-(4-Cyclohexyl-phenyl)-3-hydroxy-4-methyl-pentanoic acid ethyl ester 
• 53207-41-3 1-(4-Cyclohexyl-phenyl)-3-dimethylamino-2,2-dimethyl-propan-1-ol 
• 95711-60-7 3-(4-Cyclohexyl-phenyl)-3-hydroxy-4-methyl-pentanoic acid 
• 53251-97-1 1-(4-Cyclohexyl-phenyl)-3-dimethylamino-2,2-dimethyl-propan-1-one 
• 78575-28-7 1-(4-Cyclohexyl-phenyl)-2-methyl-propan-1-one oxime 

Relevant academic research and scientific papers

Study on the design, synthesis and structure-activity relationships of new thiosemicarbazone compounds as tyrosinase inhibitors

52 Structure-based thiosemicarbazone compounds bearing various substituted-lipophilic part, including substituted-benzaldehyde, substituted-phenylalkan-1-one and their biphenyl-type thiosemicarbazone analogs, were designed, synthesized and evaluated as new tyrosinase inhibitors. The results demonstrated that 22 compounds have potent inhibitory activities against tyrosinase with the IC50 value of lower than 1.0 μM. On the basis of the obtained experimental data, the structure-activity relationships (SARs) were rationally derived. Besides, the inhibition mechanism and the inhibitory kinetics of selected compounds 3d and 6e were investigated, revealing that such type of compounds were belonged to the reversible and competitive tyrosinase inhibitors. To verify the safety of these developed thiosemicarbazone compounds, four randomly selected compounds 3d, 4e, 6a and 9a were also tested in 293T cell line for the evaluation of the cytotoxicity. Interestingly, all these compounds almost did not perform any toxicity to 293T cells even at a high concentration of 1000 μmol/L. Taken together, these results suggested that such compounds could serve as the highly efficient and more safe candidates for the treatment of tyrosinase-related disorders.